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eperfusion Strategies for Acute
yocardial Infarction in the Elderly
enefits and Risks
ajendra H. Mehta, MD, MS,* Christopher B. Granger, MD,* Karen P. Alexander, MD,*
duardo Bossone, MD,† Harvey D. White, MD,‡ Michael H. Sketch, JR, MD*
urham, North Carolina; Brindisi, Italy; and Auckland, New Zealand
The optimal reperfusion strategy in elderly patients with ST-segment elevation myocardial
infarction (STEMI) remains a topic of debate. This lack of consensus stems from the
exclusion or under-representation of the elderly in clinical trials. This review evaluates the
available literature pertaining to reperfusion therapy for the treatment of STEMI in the
elderly. We identified all published studies evaluating the effectiveness of thrombolytic
therapy, primary percutaneous coronary intervention (PCI), or adjunctive therapies to
reperfusion by conducting an electronic search of MEDLINE through December 2003.
Meta-analysis of clinical trials suggests a survival benefit of thrombolytic therapy in the elderly
with STEMI, whereas some observational studies have raised concerns about the lack of
short-term benefit or possibility of harm with thrombolysis. However, most observational
studies demonstrate improved intermediate-term survival with thrombolysis. In contrast,
multiple clinical trials and observational studies indicate improved survival and low risk of
stroke with primary PCI compared with thrombolysis in elderly patients with STEMI.
Information on the efficacy of newer antithrombotic agents as adjunct to thrombolysis or
primary PCI is scarce. Available data suggest an increased risk of intracerebral bleeding with
the combination of a fibrin-specific agent and a glycoprotein IIb/IIIa receptor antagonist in
patients75 years of age. Clearly targeted large-scale clinical trials are needed to evaluate the
relative merits of available reperfusion strategies as well as newer antithrombotic adjunctive
therapies in the elderly with STEMI. (J Am Coll Cardiol 2005;45:471–8) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.065American College of Cardiology Foundation
5
y
a
t
s
d
t
n
s
r
e
r
s
C
2
I
T
I
f
M
i
hespite the greater incidence and risk of ST-segment
levation myocardial infarction (STEMI) among older pa-
ients (1–3), several large randomized clinical trials evaluat-
ng reperfusion therapy for the treatment of these patients
3,4) or the relative merits of mechanical versus chemical
eperfusion (5) have systematically excluded elderly patients.
ven trials that have included older patients have substan-
ially underrepresented them, with only 10% to 15% of the
opulations being 75 years of age (4,6–8). Thus, much
ess is known about the risk/benefits of reperfusion therapy
r the optimal reperfusion strategy among the elderly with
TEMI. The lack of data regarding reperfusion for STEMI
n the elderly, combined with atypical symptoms, high levels
f comorbidity, and delayed presentation, have all poten-
ially contributed to the significant underutilization of such
reatment in this cohort (2,9,10). Older age is one of the key
redictors of failure to use reperfusion therapy in otherwise
ligible patients (2,9,10). The proportion of “ideal” elderly
atients receiving reperfusion therapy decreases as age
ncreases (64.8%, 65 to 69 years; 60.1%, 70 to 74 years;
From the *Duke Clinical Research Institute and Duke University Medical Center,
urham, North Carolina; †National Research Council of Southern Italy, Brindisi,
taly; and ‡Auckland City Hospital, Auckland, New Zealand.t
Manuscript received June 16, 2004; revised manuscript received October 3, 2004,
ccepted October 18, 2004.0.4%, 75 to 79 years; 35.4%, 80 to 84 years; 20.4%, 85
ears) (10).
The main objective of this review is to evaluate the
vailable literature pertaining to reperfusion therapy for the
reatment of STEMI in the elderly. An extensive electronic
earch of MEDLINE through December 2003 was con-
ucted in order to identify all published studies evaluating
he effectiveness of fibrinolytic therapy, percutaneous coro-
ary intervention (PCI), or adjunctive therapies to reperfu-
ion for treatment of STEMI in the elderly. In addition to
eviewing the reference list of each identified study, we
xamined existing bibliographies of relevant studies and
eview articles. Finally, we reviewed scientific session ab-
tracts in Circulation, Journal of the American College of
ardiology, and European Heart Journal through December
003.
NTRAVENOUS THROMBOLYTIC
HERAPY IN THE ELDERLY WITH STEMI
ntravenous thrombolysis remains the most common reper-
usion strategy for the treatment of patients with STEMI.
ore recent trials and registries have provided important
nsights into the risks and benefits of thrombolysis in this
igh-risk cohort (2,6–9). Randomized clinical thrombolytic
rials and registry data show that the risk of intracranial
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Reperfusion Strategies in the Elderly February 15, 2005:471–8emorrhage increases with age, more so with fibrin-specific
gents than with nonspecific agents (6–8,11–12). Despite
his increased risk, thrombolysis appears to be beneficial in
ecreasing mortality in the elderly (3).
ata from randomized clinical trials. The Fibrinolytic
herapy Trialists’ collaborative group found that younger
atients with STEMI have a slightly greater relative reduc-
ion in mortality compared with elderly patients, but the
igher absolute mortality in the elderly results in higher
bsolute mortality reduction (3). Thus, a 26% reduction in
ortality in patients 55 years of age resulted in 11 lives
aved per thousand patients treated in this age group. In
ontrast, although there was only a 15% reduction in
ortality in patients 75 years of age, this resulted in 34
ives saved per thousand patients treated in this age group
Fig. 1) (3,13). Similarly, White et al. (14) examined the
ffects of age on outcomes in patients enrolled in the Global
tilization of Streptokinase and Tissue plasminogen acti-
ator for Occluded coronary arteries-I (GUSTO-I) trial and
ound that the greatest absolute reduction in mortality with
hrombolysis occurred in patients 65 to 85 years of age.
urthermore, the net benefit (mortality and/or disabling
troke) was greater with tissue plasminogen activator versus
treptokinase. In contrast, the net benefit favored streptoki-
ase among patients 85 years of age. However, because of
he small number of patients 85 years of age enrolled in
he trial (1% of the study population), these investigators
uggested using caution in making any firm conclusions
rom this data regarding efficacy of specific fibinolytic agents
mong patients in this age group.
Newer thrombolytic agents such as reteplase, tenec-
eplase, and lanoteplase have not been proven to be superior
o tissue plasminogen activator in reducing mortality in
TEMI patients. However, the Asessment of Safety and
fficacy of a New Thrombolytic (ASSENT) investigators
emonstrated that, compared with bolus and infusion of
issue plasminogen activator, the increased fibrin-specific
enecteplase was associated with lower rates of major bleed-
ng (15.15% vs. 8.33%) as well as intracranial hemorrhage
3.02% vs. 1.14%) in the high-risk cohort of elderly females
75 years of age and weighing 67 kg (15). In addition,
hen these investigators compared adjunctive heparin dos-
Abbreviations and Acronyms
ASSENT  Assessment of Safety and Efficacy of a
New Thrombolytic trial
CI  confidence interval
HR  hazard ratio
MIR  Myocardial Infarction Registry
MITRA  Maximum Individual Therapy in Acute
Myocardial Infarction trial
OR  odds ratio
PCI  percutaneous coronary intervention
RR  relative risk
STEMI  ST-segment elevation myocardial infarctionng of tenecteplase in the ASSENT-2 and -3 trials (doses of
F
Fhich were similar in the two studies), they found that the
ower dose of weight-based heparin used in the ASSENT-3
rial was associated with lower major bleeding rates com-
ared with the higher heparin dose used in the ASSENT-2
rial (adjusted odds ratio [OR] 0.49, 95% confidence inter-
al [CI] 0.35 to 0.67), particularly in patients weighing70
g (16).
ata from observational registries. Some observational
tudies have raised concerns about the lack of short-term
urvival benefit or the possibility of harm with thrombolysis
17–19). Thiemann et al. (17) examined patients from the
ooperative Cardiovascular Project and found that while
urvival among patients receiving thrombolysis was better in
hose 65 to 75 years of age, it was significantly lower in
hose 75 years of age, particularly women. Angeja et al.
18) examined data from the National Registry of Myocar-
ial Infarction-2 and found that, compared with patients
eceiving no reperfusion therapy, tissue plasminogen
ctivator-treated patients had lower rates of in-hospital
eath and the composite of in-hospital death or stroke if
hey were 85 years of age, whereas no such benefit was
bserved among those 85 years of age. Similarly, Soume-
ai et al. (19) evaluated 2,659 patients 65 years of age
dmitted with STEMI to community hospitals in Minne-
ota between 1992 and 1996 and found that, compared with
o reperfusion, thrombolytic therapy was associated with
ower in-hospital mortality in eligible patients 80 years of
ge, but the odds of death increased 1.4-fold in those 80
ears of age.
In contrast, other investigations have shown that, al-
hough there is no reduction in short-term mortality,
ntermediate-term mortality is significantly reduced by in-
ravenous thrombolysis in this cohort. A combined analysis
rom the Maximum Individual Therapy in Acute Myocar-
ial Infarction (MITRA) trial and Myocardial Infarction
egistry (MIR) demonstrated that thrombolytic therapy
ad no impact on in-hospital mortality among patients aged
75 years of age, but was associated with a significant
eduction in 18-month mortality when compared with no
eperfusion (OR 0.58; 95% CI 0.39 to 0.88) (20). Similarly,
n an analysis of patients65 years of age, Berger et al. (21)
howed no impact of thrombolysis on 30-day mortalityigure 1. Benefits of thrombolytic therapy in different age groups. FTT 
ibrinolytic Therapy Trialists.
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February 15, 2005:471–8 Reperfusion Strategies in the Elderlyhazard ratio [HR] 1.01; 95% CI 0.94 to 1.09), but there
as a significant association with lower mortality at one year
HR 0.84; 95% CI 0.79 to 0.89). The beneficial effect of
ntravenous thrombolysis was also reported by Stenestrand
t al. (22) among Swedish STEMI patients 75 years of
ge, with a significant reduction in one-year mortality
relative risk [RR] 0.88; 95% CI 0.79 to 0.97).
NTRAVENOUS THROMBOLYSIS VERSUS
RIMARY PCI IN THE ELDERLY WITH STEMI
ata from randomized clinical trials. Many randomized
rials have shown more favorable short-term outcomes in
TEMI patients with the use of primary PCI rather than
ith thrombolytic therapy (5). However, these trials did not
pecifically evaluate elderly patients, thereby limiting the
xtrapolation of their findings to this cohort. Nevertheless,
ubset analysis in two trials suggested that primary PCI may
e more effective than thrombolytic therapy in elderly
atients (23,24). In the Primary Angioplasty in Myocardial
nfarction study, 38% of patients enrolled were65 years of
ge (23). This investigation showed a trend towards fewer
eaths (5.7% vs. 15.0%; p  0.066), lower rate of recurrent
schemia (8.6% vs. 20%; p  0.048), and a lower composite
ate of recurrent myocardial infarction and death (8.6% vs.
7.5%; p  0.0003) in elderly patients who underwent
ngioplasty than in those who received thrombolytic ther-
py. The largest randomized trial, the Global Use of
trategies To Open occluded coronary arteries in acute
oronary syndromes-IIb (GUSTO-IIb), also showed a
rend towards lower 30-day mortality with primary PCI
han with thrombolytic therapy among patients 70 years
f age (24). The Primary Coronary Angioplasty Trialists
nvestigators studied 2,635 patients enrolled in 10 random-
zed trials of primary angioplasty versus thrombolysis (25).
hey found that, as compared with thrombolysis, primary
ngioplasty was most effective in reducing mortality at 30
ays among patients 70 years of age than in those 70
igure 2. Thirty-day mortality in patients randomized to primary coronary
ngioplasty versus intravenous thrombolysis in the Primary Coronary
ngioplasty Trialists’ Overview. Open bars  lytic; solid bars  percu-
aneous coronary intervention.ears (Fig. 2) (25).
i
PA recently published very small trial randomly assigned
atients aged 75 years with STEMI to receive either
rimary PCI (n 47) or intravenous streptokinase (n 41)
nd suggested a lower composite of death, reinfarction, or
troke at one year with primary PCI (13% vs. 44%; RR 0.19;
5% CI 0.06 to 0.59) (26). The 30-day (7% vs. 22%; RR
.25; 95% CI 0.04 to 1.11) and 1-year mortality rates (11%
s. 29%; RR 0.29; 95% CI 0.07 to 1.00) were also lower in
he primary PCI group.
ata from observational studies. Consistent with the
ndings of randomized clinical trials, four observational
tudies have suggested that primary PCI may result in lower
ortality than thrombolytic therapy in elderly patients with
TEMI (Fig. 3) (27–30).
Investigators from the Cooperative Cardiovascular
roject evaluated 234,739 patients 65 years of age with
TEMI (27). In the eligible cohort, 18,645 (23.2%) re-
eived thrombolysis, and 2,038 (2.5%) underwent primary
CI within 6 h of symptom onset. Patients treated with
rimary PCI had a lower one-year mortality rate (14.4% vs.
7.6%; adjusted HR 0.88; 95% CI 0.73 to 0.94). Among
atients without any contraindications for reperfusion, there
as a trend toward reduced 30-day mortality with primary
CI (10.1% vs. 12.0%; HR 0.84; 95% CI 0.68 to 1.03).
rimary PCI was also associated with lower rates of rein-
arction (4.0% vs. 5.3%; p  0.009), cerebral hemorrhage
0.2% vs. 1.4%; p  0.001), and other hemorrhagic end
oints (21.5% vs. 28.6%; p  0.001).
The MITRA and MIR investigators did not restrict their
nalysis to elderly patients with STEMI, but a subgroup
nalysis of patients 65 years of age showed a progressively
reater benefit of primary PCI over thrombolytic therapy
ith increasing age (28). Similarly, in a subgroup analysis of
atients with STEMI age 75 years enrolled in the
ational Registry of Myocardial Infarction-2, Tiefenbrunn
t al. (29) found a lower rate of combined end point of death
nd non-fatal stroke favoring primary PCI over alteplase
14.6% vs. 18.4%, p  0.03). Finally, Mehta et al. (30)
nalyzed 2,975 patients 70 years of age with STEMI
nrolled in the Global Registry of Acute Coronary Events
igure 3. Outcomes of patients undergoing primary percutaneous coronary
nterventions versus intravenous fibrinolysis from observational studies.
In-hospital mortality; **for ideal patients; combined in-hospital mortal-
ty and stroke in patients with acute myocardial infarction without shock.
CI  percutaneous coronary intervention; TT  thrombolytic therapy.
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Reperfusion Strategies in the Elderly February 15, 2005:471–8ho were eligible for reperfusion therapy. In this eligible
ohort, 769 (26.7%) received thrombolysis, whereas 365
12.7%) underwent primary PCI within 6 h of symptom
nset. Patients treated with primary PCI had lower in-
ospital mortality (14.4% vs. 17.6%; adjusted OR 0.62; 95%
I 0.39 to 0.96). Primary PCI was also associated with
ower rates of reinfarction (1.0% vs. 5.7%; p  0.003) and a
rend toward lower rates of stroke (1.1% vs. 2.8%; p 0.08).
n contrast, there was a trend for higher major bleeding rates
n the primary PCI group (8.6% vs. 5.9%; p  0.09).
tenting versus balloon angioplasty during primary
CI. No randomized clinical trial has evaluated primary
oronary angioplasty versus stenting in elderly with
TEMI. A subgroup analysis from the Controlled Abcix-
mab and Device Investigation to Lower Late Angioplasty
omplications trial has suggested that stent implantation
uring primary PCI is more effective in reducing the
ombined end point of death, recurrent myocardial infarc-
ion, disabling stroke, and/or ischemia-driven target vessel
evascularization than balloon angioplasty alone in patients
65 years of age (OR 0.58; 95% CI 0.38 to 0.85) (31).
mergency revascularization versus initial medical stabi-
ization for elderly patients with cardiogenic shock com-
licating myocardial infarction. Patients with cardiogenic
hock were specifically excluded from almost all randomized
rials that compared primary PCI with intravenous throm-
olysis and from the analysis of all observational studies
valuating the relative efficacy of the two reperfusion strat-
gies. The SHOCK trial randomly assigned patients with
hock due to left ventricular failure complicating myocardial
nfarction to emergency revascularization, either with PCI
r coronary artery bypass grafting (n  152), or to initial
edical stabilization (n  150) (32). While six-month
ortality was lower in the revascularization group than in
he medical therapy group (50.3% vs. 63.1%; p  0.027),
igure 4. Thirty-day death, reinfarction, and recurrent angina in patients
nd enoxaparin (Enox) and half-dose teneteplase and full-dose abciximab (A
nfractionated heparin (UFH).his benefit was only observed among patients age75 years Pf age, not in those age 75 years, raising the question of
hether there may be less benefit in the elderly.
In contrast, elderly patients with shock who were clini-
ally selected in the nonrandomized SHOCK registry to
ndergo revascularization reported marked survival benefit
ompared with those that underwent late or no revascular-
zation (33). Similarly, two other large registries demon-
trated significant survival benefit in patients selected on the
asis of physician’s judgment for an invasive strategy
34,35). Thus, elderly with STEMI and shock require
ndividualized consideration for revascularization (1).
DJUNCTIVE THERAPIES DURING
EPERFUSION IN ELDERLY WITH STEMI
s with reperfusion therapy, randomized clinical trials
rovide limited information on the risks and benefits of
ntithrombin agents (unfractionated or low-molecular-
eight heparin or direct thrombin inhibitors [hirudin and
ts analogues]) or platelet glycoprotein IIb/IIIa receptor
ntagonists as adjunctive therapies during thrombolysis or
echanical reperfusion in elderly patients with STEMI.
ubgroup analyses from some of these trials have provided
nsight into the merits versus risks of such adjunctive
reatments.
ow-molecular-weight heparins. While no data are avail-
ble on the use of low-molecular-weight heparin in elderly
atients with STEMI undergoing primary PCI, subgroup
nalysis in the ASSENT-3 trial suggested similar benefits of
ow-molecular-weight heparin over weight-adjusted unfrac-
ionated heparin in reducing the 30-day composite of death,
n-hospital reinfarction, refractory ischemia, intracranial
emorrhage, or major bleeding when given in combination
ith full-dose tenecteplase in patients with STEMI 75
ears of age (Fig. 4) (36). However, in the ASSENT-3
ars of age and in those75 years of age treated with full-dose tenecteplase
ompared with those treated with full-dose abciximab and weight-adjusted75 yeLUS trial, which compared enoxaparin with weight-
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February 15, 2005:471–8 Reperfusion Strategies in the Elderlydjusted unfractionated heparin in a prehospital setting,
here was an unacceptably high risk of intracranial hemor-
hage with enoxaparin in the elderly (2.2% vs. 0.97%; p 
.047) (37). This may relate to an excessive dose of
noxaparin in the elderly population with decreased creati-
ine clearance, and underscores the importance of having
ufficient data on appropriate doses of low-molecular-
eight heparin in elderly populations to specifically evaluate
isks and benefits.
irect thrombin inhibitors. Similarly, no data are avail-
ble on the risks/benefits of direct thrombin inhibitors in
lderly patients with STEMI undergoing primary PCI.
owever, two trials reported the role of direct thrombin
nhibitors among the elderly as an adjunct to thrombolysis
n subgroup analysis (38,39). Antman et al. (38) compared
irudin with unfractionated heparin as adjunctive therapy to
treptokinase or front-loaded tissue plasminogen activator,
nd suggested no advantage of this direct thrombin inhib-
tor over unfractionated heparin as an adjunct to thrombol-
sis in patients 65 years of age. Similarly, the Hirulog and
arly Reperfusion/Occlusion-2 investigators reported no
ifference in 30-day mortality in patients 65 years of age
ith STEMI treated with bivalirudin or weight-adjusted
nfractionated heparin as adjunct to streptokinase, but
oted a trend toward lower in-hospital reinfarction in the
ivalirudin-treated patients. However, there was also a trend
oward higher intracranial hemorrhage in the patients 75
ears of age treated with bivalirudin than in those receiving
nfractionated heparin (1.0% vs. 0.5%; p  0.16) (39).
lycoprotein IIb/IIIa receptor antagonists. Data on the
afety and efficacy of glycoprotein IIb/IIIa receptor antag-
nist together with half-dose thrombolytic therapy for
atients with STEMI has been reported in subgroup anal-
sis of two large-scale randomized clinical trials (36,40).
he ASSENT-3 investigators reported that, in patients
75 years of age, there was a trend towards higher 30-day
ortality in patients treated with the combination of te-
ecteplase and abciximab (22.3%) compared with those
igure 5. Risk of intracranial hemorrhage (ICH) in patients 75 years of
ge and in those age 75 years enrolled in Global Use of Strategies To
pen occluded coronary arteries in acute myocardial infarction (GUSTO-V)
nd Assessment of Safety and Efficacy of a New Thrombolytic-3
ASSENT-3) treated with half-dose thrombolytics and full-dose abciximab
ersus those treated with full-dose thrombolytics alone. Open bars  lytic;
olid bars  lytic  glycoprotein IIb/IIIa.reated with tenecteplase and unfractionated heparin r15.9%) or tenecteplase and low-molecular-weight heparin
15.6%) (p  0.11). Furthermore, the risk for major
leeding complications was threefold higher with full-dose
bciximab and half-dose tenecteplase as compared with
ull-dose tenecteplase (2.6% vs. 0.7%) (Fig. 5) (36). Even
hough combination therapy had similar 30-day rates of
omposite of death, in-hospital reinfarction, or refractory
schemia in patients 75 years of age (efficacy end point,
R 1.02; 95% CI 0.76 to 1.36), the composite of efficacy
lus safety end point (intracranial hemorrhage or major
leeding) was 30% higher in the combination therapy group
OR 1.30; 95% CI 1.01 to 1.68) (Figs. 4 and 5) (36). The
USTO-V trial, which compared standard-dose reteplase
ersus half-dose reteplase with full-dose abciximab in pa-
ients with STEMI presenting within 6 h of symptom
nset, showed no advantage of combination therapy in
educing the 30-day mortality among patients 75 years of
ge (18.3% vs. 17.9%; p  0.83) (40). However, the risk of
ntracranial hemorrhage in patients 75 years of age was
wice as high in the combination group as compared with
he full-dose thrombolytic-treated patients (2.1% vs. 1.1%;
 0.069) (Fig. 5).
In contrast with the increased risk of bleeding (and no
ifference in mortality) with glycoprotein IIb/IIIa receptor
ntagonists in combination with thrombolytic therapy
36,40), the subgroup analysis from the Abciximab Before
irect Angioplasty and Stenting in Myocardial Infarction
egarding Acute and Long-Term Follow-up trial suggested
o such increased risk of major bleeding with abciximab
hen used as an adjunct to stent implantation during
rimary PCI among patients 65 years of age (41). The
0-day (RR 0.30; 95% CI 0.09 to 0.99) and 6-month (RR
.35; 95% CI 0.12 to 0.98) composite end points of death,
einfarction, or urgent target vessel revascularization were
ignificantly lower in patients65 years of age who received
bciximab compared with placebo (41). No data exist on the
enefits and risk of other glycoprotein IIb/IIIa receptor
lockers as adjunct to chemical or mechanical reperfusion in
he elderly.
LINICAL IMPLICATIONS AND FUTURE DIRECTIONS
suggested approach to reperfusion in elderly is shown in
igure 6. The optimal reperfusion strategy in this rapidly
rowing segment of the population remains to be estab-
ished in large-scale randomized clinical trials. Until results
f such trials are available, current data indicate that, when
vailable, rapid primary PCI (preferably in a high-volume
enter) is particularly attractive as more elderly are eligible,
nd it improves reperfusion, reduces recurrent ischemia/
nfarction, and reduces the risk of intracranial bleeding as
ompared with thrombolytics in this cohort. In contrast,
imely primary PCI is not available at most centers, and the
isk of major bleeding (mainly at vascular access sites) is
ncreased with PCI. In addition, the risk of renal failure
emains an important concern with primary PCI. While
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Reperfusion Strategies in the Elderly February 15, 2005:471–8rimary PCI may be considered the reperfusion strategy of
hoice for elderly patients with STEMI in high-volume
ospitals that can achieve rapid time to reperfusion, the
roven benefits of thrombolytic therapy should prompt
ider use in the elderly in most centers where rapid primary
CI is not available. Efficient systems of transfer may
rovide the opportunity for wider use of primary PCI,
specially for patients with contraindications to thrombol-
sis.
igure 6. Recommended approach to reperfusion therapy for patients
eight-adjusted unfractionated heparin  60 U/kg bolus (maximum 4,000
oronary artery bypass grafting; EMS  emergency medical service; GP Based on the studies presented, should all elderly patients mith STEMI who present to hospitals where primary PCI
s unavailable be transferred immediately to centers that
ffer it? The inherent time delay in the transfer of patients
or primary PCI may offset the relative time-sensitive
enefits of reperfusion with this strategy. Rapid initiation of
hrombolysis should be considered in these elderly patients
n whom timely mechanical reperfusion is not feasible. In no
ther cohort is the concept of net clinical benefit (mortality
enefit weighed against the risk of hazard) of thrombolysis
65 years with ST-segment elevation myocardial infarction. *Dose of
ollowed by infusion at 12 U/kg/h (maximum dose 1,000 U/h). CABG 
oprotein; PCI  percutaneous coronary intervention.age 
U) fore important than in the elderly. Therapy and choice of
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February 15, 2005:471–8 Reperfusion Strategies in the Elderlygents (fibrin-specific vs. nonspecific agents) should be
ndividualized and based on the risk of mortality and the
isk of stroke estimated using published models (1–3,11,12).
reliminary data support the use of weight-based fibrin-
pecific agent tenecteplase with weight-adjusted heparin as
tilized in the ASSENT-3 trials among this age group (36).
urrent national guidelines for STEMI management des-
gnates class III indication to the concomitant use of
lycoprotein IIb/IIIa antagonist and low-molecular-weight
eparin with fibrinolytic therapy in patients with STEMI
5 years and should be avoided in this age group (1).
eduction in the dose of heparin in older patients, as
uggested in the preceding text, and close and early moni-
oring of anticoagulation activity may be beneficial in
educing the risk of intracranial hemorrhage and major
leeding as well as in improving survival in elderly patients
eceiving fibrinolysis. Recent trials have reported extremely
ow rates of intracranial hemorrhage (0.5% to 1.1%) among
lderly patients with proper patient selection, weight-
djusted heparin dosing, and close early monitoring of
nticoagulation activity (36,37,39).
Decisions regarding transfer after thrombolysis can be
ased on the clinical course of individual patients. A newer
trategy, currently under investigation, is one of facilitated
CI, wherein a patient receives half-dose thrombolytic
herapy with full-dose glycoprotein IIb/IIIa inhibitor, fol-
owed by rapid transfer to a hospital where PCI can be
erformed. Studies that have evaluated facilitated PCI have
ot reported any data on the benefits and risk of this
reatment strategy in the elderly (42,43). Given the unac-
eptably high risk of such combination therapy in the elderly
n trials to date, it remains to be established in future trials
f the strategy of facilitated PCI would be a good option for
he elderly.
Clearly targeted large-scale clinical trials are needed to
valuate the relative merits of the available reperfusion
trategies (immediate primary PCI, transfer for primary
CI even when a significant delay is anticipated during
ransfer, thrombolysis, or facilitated PCI) as well as adjunc-
ive therapies (low-molecular-weight heparin, glycoprotein
Ib/IIIa inhibitors, and direct thrombin inhibitors) in the
lderly with STEMI. Avoiding selection bias and assuring
nclusion of substantial proportions of older patients in most
andomized clinical trials may further our understanding
egarding the optimal reperfusion strategy in this cohort.
inally, prospective and retrospective registries including
he elderly with STEMI are needed to define patterns of
are, and may help to refine our understanding of a number
f issues that remain unanswered regarding reperfusion in
he elderly.
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